Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …

Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …

Patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer
(NSCLC) often develop resistance to current standard third-generation EGFR tyrosine …

In the United States, lung cancer is the second most frequently diagnosed type of cancer
and the leading cause of cancer deaths. 1 Non–small-cell lung cancer (NSCLC), which …

Targeted therapies have revolutionized the treatment and improved the outcome for
oncogene-driven NSCLC and an increasing number of oncogenic driver therapies have …

Aberrant MET signaling can drive tumorigenesis in several cancer types through a variety of
molecular mechanisms including MET gene amplification, mutation, rearrangement, and …

Abstract Background In 2013, the French National Cancer Institute initiated the AcSé
program to provide patients with secure access to targeted therapies outside of their …

Simple Summary The treatment of advanced and metastatic non-small cell lung cancer
(NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics …

Uncontrolled hemorrhage and wound infection are crucial causes of trauma-associated
death in both the military and the clinic. Therefore, developing an efficient and rapid …

Abstract Background Jinshui Huanxian formula (JHF), a traditional Chinese medicine (TCM),
has been demonstrated to attenuate idiopathic pulmonary fibrosis (IPF). The active …